



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • **CIN : L24233MP1985PLC002709**

Date:09/02/2017

To,
The Company Secretary,
Corporate Compliance Department
The National Stock Exchange of India
Limited
Bandra Kurla Complex, Mumbai

To,
The Company Secretary
Corporate Compliance Department
BSE Limited
Dalal Street, P.J. Tower, Mumbai

Sub: Approval of Un Audited Financial Result for the quarter ended on 31st December 2016 and Limited Review Report thereon

Scripe Code: 524396; Sripe Id: BIOFILCHEM; ISIN No: INE829A01014

Dear Sir/Madam

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today, has approved the Un Audited Financial Result for the quarter ended on 31st December 2016 and Limited Review Report thereon.


Copy of audited financial result along with Limited Review Report is enclosed with this letter and copy of the same is also available* on website of the Company. i.e www.biofilgroup.net

This is for your information and record.

Thanking you,

Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited


Shikha Khilwani
Company Secretary & Compliance Officer
Meb No:43203





S.N. Gadiya & Co.
(Chartered Accountants)

Satya Narayan Gadiya
F.C.A., B. Com.
Mob. : 9301503126

Limited Review Report


The Board of Directors,
M/S Biofil Chemicals And Pharmaceuticals Limited
11/12, Sector E Sanwer Road
Industrial Area
Indore 452015 -M.P.

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter ended 31st December 2016 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For S.N. Gadiya & Co.
Chartered Accountants
FRN: 002052C

S.N. Gadiya
Proprietor
M. No.071229

Date 09.02.2017
Place:-Indore

241, Apollo Tower, 2, M.G. Road, Indore-1 Ph. : 07314069030
Resi. : 15, Textile Clerk Colony, Indore-10 Ph. : 07314031266
E-mail : satya_mewar@rediffmail.com

Un-Audited Financial Results of Quarter and Nine Month Ended of 31st Dec . 2016
31-12-2015 of M/s. Biofil Chemicals & Pharmaceuticals Limited
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN NO. L24233MP1985PLC002709

Un-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st December , 2016

(Rs in Lacs Except EPS and Face value of share)

Statement of Standalone Unaudited Financial Results for the Quarter & nine Months ended 31st December 2016							
Particulars	3 months ended (31/12/2016)	Preceding 3 months ended (30/09/2016)	Corresponding 3 months ended in the previous year (31/12/2015)	Year to date figures for current period ended (31/12/2016)	Year to date figures for the previous year ended (31/12/2015)	Previous year ended (31/03/2016)	
	Revised	Revised	Revised	Revised	Revised	Audited	
1 Income from operations							
(a) Net sales/ income from operations (Net of Excise duty)	396.17	292.45	680.54	720.41	798.11	1085.65	
(b) Other operating income	0.55	-	8.90	1.68	17.06	251.65	
Total income from operations (net)	396.71	292.45	689.44	722.08	815.17	1337.30	
2 Expenses							
(a) Cost of materials consumed	29.32	13.68	23.38	60.19	74.08	121.34	
(b) Purchases of stock-in-trade	253.68	172.60	899.85	431.08	930.63	932.53	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(12.52)	6.42	(280.52)	(17.35)	(284.49)	0.58	
(d) Employee benefits expense	12.71	10.54	8.17	27.82	20.26	48.23	
(e) Depreciation and amortisation expense	6.51	6.53	6.26	19.57	19.79	26.49	
(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	54.05	54.98	20.27	113.85	41.97	127.42	
Total expenses	343.76	264.76	677.41	635.17	802.24	1256.58	
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	52.96	27.69	12.02	86.92	12.92	80.71	
4 Other income	0.00	3.45	3.86	3.45	24.57	32.55	
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	52.96	31.14	15.89	90.37	37.50	113.26	
6 Finance costs	3.75	3.75	3.75	11.25	11.22	15.19	
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	49.21	27.39	12.14	79.12	26.28	98.07	
8 Exceptional items						1.12	
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	49.21	27.39	12.14	79.12	26.28	96.95	
10 Tax expense						18.69	
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	49.21	27.39	12.14	79.12	26.28	78.26	
12 Extraordinary items (net of tax Rs expense lakhs)							
13 Net profit/(loss) for the period (11+12)	49.21	27.39	12.14	79.12	26.28	78.26	
14 Share of Profit/Loss of Associates							
15 Minority Interest							
16 Net Profit/(loss) after taxes, minority interest and share of profit/(Loss) of associates after tax (13+14+15)	49.21	27.39	12.14	79.12	26.28	78.26	
17 Paid up Equity Share Capital	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38	
(Face value of share Rupees each)	10.00	10.00	10.00	10.00	10.00	10.00	
18 Reserve excluding Revaluation Reserve as per the Balance Sheet of previous accounting year						(913.35)	
19.i Earnings per share (before extraordinary items)							
(of Rs. 10/- each) (not annualised):							
(a) Basic	0.302	0.168	0.075	0.486	0.161	0.481	
(b) Diluted	0.302	0.168	0.075	0.486	0.161	0.481	
19.ii Earnings per share (after extraordinary items)							
(of Rs. 10/- each) (not annualised):							
(a) Basic	0.302	0.168	0.075	0.486	0.161	0.481	
(b) Diluted	0.302	0.168	0.075	0.486	0.161	0.481	


[Handwritten Signature]


[Circular Stamp: Biofil Chemicals & Pharmaceuticals Limited, INDORE]

- The above unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 9th Day of February, 2017
- The "Limited Review" of the financial results for the quarter ended 31st December 2016 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been carried out by the Statutory Auditors.
- Previous year period's/year's figures have been regrouped wherever necessary to conform to the current period's classification.
- The Company has reported segment wise information as per Accounting Standard (AS-17), in terms of Companies Accounting Standard Rules, 2006. The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
 1. Pharma Division
 2. Chemicals Division
 3. Plastic Division
- The provision for deferred tax and NPA, if any will be considered at the end of the year.
- The aforesaid Unaudited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

Date **09.02.2017**

Place **Indore**


RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709

Segmentwise Revenue, Results an Capital Employed for Quarter and Nine Month ended 31st Dec 2016

Rs. In lacs

S.No	Segment Revenue	Quarter Ended			Nine Month Ended		31 March 2016
		Dec 31 , 2016	Sep 30 , 2016	Dec 31 , 2015	Dec 31 , 2016	Dec 31 , 2015	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
		31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
1	Segment Revenue (net sale/income from each segment should be disclosed under this head)						
	(a) Pharma Division	357.07	179.36	653.77	542.59	680.48	1160.00
	(b) Chemical Division	38.10	34.12	20.64	97.85	101.51	134.524
	(c) Plastic Division	1.00	0.00	6.13	1.00	16.12	22.624
	(d) Unallocated	0.55	82.42	12.76	84.10	41.63	52.696
	Net Sales / Income from Operations	396.71	295.89	693.30	725.53	839.74	1369.85
2	Segment Results (Profit)(+)/Loss(-) before tax and interest from Each segment)						
	(a) Pharma Division	56.70	35.09	7.11	96.23	9.07	148.07
	(b) Chemical Division	0.31	2.28	6.79	8.12	31.75	(32.02)
	(c) Plastic Division	(4.05)	(6.24)	1.99	(13.98)	(3.29)	(7.39)
	(d) Unallocated	-	-	-	-	-	2.29
	Total	52.96	31.14	15.89	90.37	37.53	110.95
	Less : 1) Interest	3.75	3.75	3.75	11.25	11.25	15.06
	ii) Other Un-allocable Expenditure net off						2.18
	iii) Un-allocable Income						
	Profit Before Tax	49.21	27.39	12.14	79.12	26.28	98.07
	Total Profit Before Tax	49.21	27.39	12.14	79.12	26.28	98.07
3	Segment Assets (A)						
	Pharma Division	1242.61	773.35	1491.75	1242.61	1491.75	1554.61
	Chemicals Division	772.24	768.83	832.83	772.24	832.83	761.22
	Plastic Division	78.34	81.08	88.11	78.34	88.11	97.37
	Other	-	-	-	-	-	-
	Total (A)	2,093.19	1,623.26	2,412.70	2,093.19	2,412.70	2,413.19
4	Segment Liabilities (B)						
	Pharma Division	736.48	372.05	1333.84	736.48	1333.84	1158.44
	Chemicals Division	20.90	37.75	112.04	20.90	112.04	38.99
	Plastic Division	148.59	148.94	137.33	148.59	137.33	143.78
	Other	-	-	-	-	-	-
	Total (B)	905.96	558.74	1,583.21	905.96	1,583.21	1,341.21
	Total Capital Employed	1187.23	1064.52	829.49	1187.23	829.49	1071.99

DATE : 09-02-2017
PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
(DIN : 00028819)

